Amol Akhade Highlights ROSELLA trial Results on Relacorilant in Platinum-Resistant Ovarian Cancer

Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X:

“ROSELLA trial – ESMO GynaeCancer

Platinum-resistant ovarian cancer

Testing relacorilant (SGRA) + nab-paclitaxel vs nab-paclitaxel alone

MOA: Relacorilant = Selective Glucocorticoid Receptor Antagonist

Blocks cortisol’s anti-apoptotic effect

Potentiates chemo response without added toxicity

PFS (by BICR): 6.5 vs 5.5 mo | HR 0.70 | P = 0.0076
OS (interim): 16.0 vs 11.5 mo | HR 0.69 | P = 0.0121
12-mo OS: 60% vs 49%

 Benefit consistent in:

– Primary platinum-refractory
– 1–6 months platinum-free interval
– No biomarker required
– Well tolerated
– A first-in-class chemo sensitizer may be here!”